Developer docs
API playgroundTry for free, no card

Search company profiles

Mereo Biopharma

Full company profile

uuid0003d88

Namestring
Mereo Biopharma
Legal namestring
Mereo BioPharma Group plc
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Mereo BioPharma Group plc is a clinical-stage specialty biopharmaceutical company founded in 2015 and headquartered in London, UK, with operating subsidiaries in Mountain View, California (Mereo BioPharma 5, Inc.) and Amsterdam, Netherlands (Mereo BioPharma Europe B.V.). The company is publicly listed on NASDAQ (ticker: MREO), was previously listed on AIM (MPH), and focuses on developing therapeutics for rare diseases with limited or no treatment options, primarily osteogenesis imperfecta (OI) and alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), along with selected oncology indications.

Mereo's pipeline is built around setrusumab (UX143), a fully human anti-sclerostin monoclonal antibody for OI developed in partnership with Ultragenyx Pharmaceutical, and alvelestat (MPH-966), an oral neutrophil elastase inhibitor for AATD-LD originally licensed from AstraZeneca. The company also retains oncology assets including the anti-TIGIT antibody etigilimab (with a Celgene option inherited from the OncoMed merger) and the bispecific navicixizumab (licensed to Feng Biosciences). The company operates a capital-efficient model of acquiring clinical-stage programs that have been deprioritized by originator pharmaceutical or biotechnology companies, leveraging prior investment to reduce development risk and capital intensity.

Revenue mechanics are presently minimal and episodic, consisting of partnership milestone payments and licensing royalties rather than commercial product sales. Under the Ultragenyx agreement for setrusumab, Mereo is eligible for up to $245M in milestones plus royalties on Ultragenyx-territory sales while retaining EU and UK commercial rights. The company reported a FY2025 net loss of $41.9 million against a $41 million cash position providing runway into mid-2027. The Phase 3 ORBIT and COSMIC trials for setrusumab failed to meet their primary endpoint of reducing annualized clinical fracture rates in December 2025, triggering an 87.7% stock price decline, securities class action litigation by April 2026, and immediate cost reduction measures including active partnership discussions for remaining programs.

Short descriptiontext

Mereo BioPharma is a clinical-stage biopharmaceutical company developing therapeutics for rare diseases, primarily setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, operating through strategic partnerships with Ultragenyx and others.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, biopharmaceutical development, monoclonal antibody therapy, osteogenesis imperfecta treatment, orphan drug development
Industry2 codes
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Partnership and Milestone Payments
TypeLicensing Royalties
Description

Mereo receives potential additional milestone payments of up to $245 million and royalties from Ultragenyx on commercial sales in Ultragenyx territories for setrusumab. Mereo has retained EU and UK commercial rights and will pay Ultragenyx royalties on commercial sales in those territories.

mereobiopharma.com
2Future Product Sales
TypeOne Time License
Description

Pre-revenue biopharmaceutical company focused on developing therapies for rare diseases. Revenue potential from future commercialization of setrusumab, alvelestat, and other pipeline candidates.

mereobiopharma.com
3Out-licensed Programs
TypeLicensing Royalties
Description

Several clinical stage programs have been out-licensed. Navicixizumab partnered with Feng Biosciences Inc. Leflutrozole licensed to ReproNovo SA. These partnerships include milestone payments and royalties.

mereobiopharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mereo BioPharma is a clinical-stage specialty biopharmaceutical company developing novel therapeutics for rare diseases with limited or no treatment options. Its lead pipeline assets are setrusumab (anti-sclerostin monoclonal antibody) for osteogenesis imperfecta and alvelestat (oral neutrophil elastase inhibitor) for alpha-1 antitrypsin deficiency-associated lung disease, complemented by oncology programs (etigilimab, navicixizumab) and other out-licensed candidates. The company uses a capital-efficient acquisition model, taking on therapies deprioritized by larger pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 3 ORBIT and COSMIC studies showed statistically significant improvements in bone mineral density but did not meet primary endpoint of reducing annualized clinical fracture rates
+3 more records
Product overview1 text field

Mereo BioPharma is a clinical-stage biopharmaceutical company focused on rare diseases and oncology. The company operates a pipeline of novel therapeutic candidates, with two lead rare disease programs: Setrusumab (UX143) for osteogenesis imperfecta (OI) and Alvelestat (MPH-966) for Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). The company has retained EU and UK commercial rights for setrusumab while partnering with Ultragenyx for development. Additionally, Mereo has oncology programs including Etigilimab (anti-TIGIT antibody) and Navicixizumab for ovarian cancer, as well as earlier-stage programs including Acumapimod for COPD and Leflutrozole for hypogonadotropic hypogonadism. The company operates a capital-efficient model and forms strategic partnerships to advance its pipeline.

Product and service7 records
1Setrusumab (UX143)
CategoryClinical-stage rare disease biopharmaceutical product
Description

A fully human monoclonal antibody that inhibits sclerostin (a protein that inhibits bone-forming cells) being developed for the treatment of osteogenesis imperfecta (OI), a rare genetic bone disorder. Developed in partnership with Ultragenyx Pharmaceutical with up to $245 million in potential milestone payments plus royalties to Mereo. Mereo retains EU and UK commercial rights.

2Alvelestat (MPH-966)
CategoryClinical-stage rare disease biopharmaceutical product
Description

An oral small-molecule inhibitor of neutrophil elastase being studied for the treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD), a rare genetic condition causing lung damage and progressive emphysema. Licensed from AstraZeneca.

3Etigilimab (Anti-TIGIT/MPH-313)
CategoryClinical-stage oncology biopharmaceutical product
Description

An anti-TIGIT antibody being evaluated in combination with nivolumab for treatment of solid tumors, including clear cell ovarian cancer and other gynecological carcinomas. Part of legacy OncoMed portfolio with prior Celgene collaboration option.

4Navicixizumab
CategoryClinical-stage oncology biopharmaceutical product
Description

A bispecific antibody targeting DLL4 and VEGF for the treatment of late-line ovarian cancer. Out-licensed globally to Feng Biosciences Inc. for development and commercialization. Phase 1b data published in Journal of Clinical Oncology.

5Acumapimod (BCT-197)
CategoryClinical-stage biopharmaceutical product
Description

A novel oral p38 MAP kinase inhibitor in development for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Part of Mereo's clinical-stage pipeline.

6Leflutrozole
CategoryClinical-stage biopharmaceutical product
Description

A non-steroidal aromatase inhibitor being developed for hypogonadotropic hypogonadism (HH) in reproductive medicine. Out-licensed globally to ReproNovo SA under an exclusive global license agreement.

7Vantictumab
CategoryClinical-stage biopharmaceutical product
Description

An antibody being developed for osteopetrosis, partnered with āshibio which plans a Phase 2 trial in the second half of 2026.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-04-30
Description

Partnership for Phase 1b/2 study of etigilimab in clear cell ovarian cancer at MD Anderson Cancer Center. Financed by Cancer Focus Fund in exchange for $1.5 million of Mereo shares and milestone payments.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-10-30
Description

Exclusive license and option to acquire AZD9668 (now alvelestat), an oral inhibitor of neutrophil elastase for alpha-1 antitrypsin deficiency. AstraZeneca previously conducted clinical trials with this compound.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration and license agreement for global development of setrusumab (UX143) for osteogenesis imperfecta. Partnership includes potential milestone payments of up to $245 million and royalties to Mereo on commercial sales in Ultragenyx territories. Mereo has retained EU and UK commercial rights.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner for vantictumab in osteopetrosis. āshibio plans a Phase 2 trial of vantictumab in osteopetrosis for the second half of 2026.

5Feng Biosciences Inc.
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Global licensing agreement for navicixizumab development and commercialization, including milestone payments and royalties.

mereobiopharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Exclusive global license agreement for development and commercialization of leflutrozole, a non-steroidal aromatase inhibitor for reproductive medicine.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner for navicixizumab development, previously partnered through OncoMed merger. Phase 1b data published in Journal of Clinical Oncology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Etigilimab part of OncoMed's prior collaboration with Celgene. Celgene has option to obtain exclusive license to develop and commercialize the product, with potential $35 million opt-in payment.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Ultragenyx is Mereo's primary commercial partner for setrusumab and a directly comparable rare disease biopharmaceutical company. Both companies focus on rare genetic diseases with novel therapeutic approaches and operate capital-efficient development models targeting underserved patient populations.

TypeBroad incumbent
Description

BioMarin is an established rare disease biopharmaceutical company with bone disorder and enzyme replacement therapies. BioMarin's scale, commercialization infrastructure, and similar therapeutic focus areas make it a relevant comparable for Mereo's rare disease strategy.

TypeDirect peer
Description

SOBI is a specialty biopharmaceutical company focused on rare diseases, with operations in Europe and a model similar to Mereo's capital-efficient approach to acquiring and developing orphan therapies for underserved patient populations.

TypeBroad incumbent
Description

Alexion is a leading rare disease biopharmaceutical company (now part of AstraZeneca) with a complementary rare disease franchise. Their specialization in rare genetic disorders and established commercialization infrastructure make them a comparable for Mereo's rare disease business model.

TypeBroad incumbent
Description

Amgen developed Evenity (romosozumab), an anti-sclerostin antibody that directly competes with Mereo's setrusumab in bone disorders. Amgen's established presence in bone biology and rare disease therapeutics makes them a relevant comparable.

TypeBroad incumbent
Description

Vertex Pharmaceuticals is a specialty biopharmaceutical company that has expanded into rare diseases through its CF franchise and emerging rare disease pipeline. Their capital-efficient R&D model and focus on underserved diseases is comparable to Mereo's strategy.

TypeDirect peer
Description

Recordati Rare Diseases is a specialty pharmaceutical company focused on rare diseases with operations in Europe. Their model of acquiring and commercializing rare disease treatments makes them directly comparable to Mereo's strategy.

TypeBroad incumbent
Description

Ipsen is a specialty biopharmaceutical company with rare disease and oncology franchises. Their European commercial infrastructure and focus on specialty care therapies make them relevant for Mereo's commercialization strategy in EU/UK markets.

TypeEmerging player
Description

Intercept is a smaller specialty biopharmaceutical company focused on rare liver diseases. Their similar capital constraints, regulatory challenges, and reliance on a few key assets provide a comparable profile to Mereo's current situation.

TypeEmerging player
Description

Orchard Therapeutics is a smaller clinical-stage biopharmaceutical company focused on rare diseases through gene therapy. Their similar size, clinical-stage profile, and focus on rare genetic disorders make them comparable to Mereo's structure and challenges.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mereo Biopharma

Rare Disease Biopharmaceuticalsmereobiopharma.com

Mereo BioPharma is a clinical-stage biopharmaceutical company developing therapeutics for rare diseases, primarily setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, operating through strategic partnerships with Ultragenyx and others.

What Mereo Biopharma does

Mereo BioPharma Group plc is a clinical-stage specialty biopharmaceutical company founded in 2015 and headquartered in London, UK, with operating subsidiaries in Mountain View, California (Mereo BioPharma 5, Inc.) and Amsterdam, Netherlands (Mereo BioPharma Europe B.V.). The company is publicly listed on NASDAQ (ticker: MREO), was previously listed on AIM (MPH), and focuses on developing therapeutics for rare diseases with limited or no treatment options, primarily osteogenesis imperfecta (OI) and alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), along with selected oncology indications.

Mereo's pipeline is built around setrusumab (UX143), a fully human anti-sclerostin monoclonal antibody for OI developed in partnership with Ultragenyx Pharmaceutical, and alvelestat (MPH-966), an oral neutrophil elastase inhibitor for AATD-LD originally licensed from AstraZeneca. The company also retains oncology assets including the anti-TIGIT antibody etigilimab (with a Celgene option inherited from the OncoMed merger) and the bispecific navicixizumab (licensed to Feng Biosciences). The company operates a capital-efficient model of acquiring clinical-stage programs that have been deprioritized by originator pharmaceutical or biotechnology companies, leveraging prior investment to reduce development risk and capital intensity.

Revenue mechanics are presently minimal and episodic, consisting of partnership milestone payments and licensing royalties rather than commercial product sales. Under the Ultragenyx agreement for setrusumab, Mereo is eligible for up to $245M in milestones plus royalties on Ultragenyx-territory sales while retaining EU and UK commercial rights. The company reported a FY2025 net loss of $41.9 million against a $41 million cash position providing runway into mid-2027. The Phase 3 ORBIT and COSMIC trials for setrusumab failed to meet their primary endpoint of reducing annualized clinical fracture rates in December 2025, triggering an 87.7% stock price decline, securities class action litigation by April 2026, and immediate cost reduction measures including active partnership discussions for remaining programs.

Mereo Biopharma firmographics

Firmographics
Name
Mereo Biopharma
Legal name
Mereo BioPharma Group plc
Website
https://mereobiopharma.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Mereo BioPharma is a clinical-stage biopharmaceutical company developing therapeutics for rare diseases, primarily setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, operating through strategic partnerships with Ultragenyx and others.
Ownership category
akta.pro rank

Mereo Biopharma industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Biopharmaceutical development
  • Monoclonal antibody therapy
  • Osteogenesis imperfecta treatment
  • Orphan drug development

Where Mereo Biopharma is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Mereo Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Partnership and Milestone Payments: Mereo receives potential additional milestone payments of up to $245 million and royalties from Ultragenyx on commercial sales in Ultragenyx territories for setrusumab. Mereo has retained EU and UK commercial rights and will pay Ultragenyx royalties on commercial sales in those territories.
  2. Future Product Sales: Pre-revenue biopharmaceutical company focused on developing therapies for rare diseases. Revenue potential from future commercialization of setrusumab, alvelestat, and other pipeline candidates.
  3. Out-licensed Programs: Several clinical stage programs have been out-licensed. Navicixizumab partnered with Feng Biosciences Inc. Leflutrozole licensed to ReproNovo SA. These partnerships include milestone payments and royalties.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Mereo Biopharma product offering

Product offering

Core offering

Mereo BioPharma is a clinical-stage specialty biopharmaceutical company developing novel therapeutics for rare diseases with limited or no treatment options. Its lead pipeline assets are setrusumab (anti-sclerostin monoclonal antibody) for osteogenesis imperfecta and alvelestat (oral neutrophil elastase inhibitor) for alpha-1 antitrypsin deficiency-associated lung disease, complemented by oncology programs (etigilimab, navicixizumab) and other out-licensed candidates. The company uses a capital-efficient acquisition model, taking on therapies deprioritized by larger pharmaceutical companies.

Product overview

Mereo BioPharma is a clinical-stage biopharmaceutical company focused on rare diseases and oncology. The company operates a pipeline of novel therapeutic candidates, with two lead rare disease programs: Setrusumab (UX143) for osteogenesis imperfecta (OI) and Alvelestat (MPH-966) for Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). The company has retained EU and UK commercial rights for setrusumab while partnering with Ultragenyx for development. Additionally, Mereo has oncology programs including Etigilimab (anti-TIGIT antibody) and Navicixizumab for ovarian cancer, as well as earlier-stage programs including Acumapimod for COPD and Leflutrozole for hypogonadotropic hypogonadism. The company operates a capital-efficient model and forms strategic partnerships to advance its pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Setrusumab (UX143) A fully human monoclonal antibody that inhibits sclerostin (a protein that inhibits bone-forming cells) being developed for the treatment of osteogenesis imperfecta (OI), a rare genetic bone disorder. Developed in partnership with Ultragenyx Pharmaceutical with up to $245 million in potential milestone payments plus royalties to Mereo. Mereo retains EU and UK commercial rights.
  • Alvelestat (MPH-966) An oral small-molecule inhibitor of neutrophil elastase being studied for the treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD), a rare genetic condition causing lung damage and progressive emphysema. Licensed from AstraZeneca.
  • Etigilimab (Anti-TIGIT/MPH-313) An anti-TIGIT antibody being evaluated in combination with nivolumab for treatment of solid tumors, including clear cell ovarian cancer and other gynecological carcinomas. Part of legacy OncoMed portfolio with prior Celgene collaboration option.
  • Navicixizumab A bispecific antibody targeting DLL4 and VEGF for the treatment of late-line ovarian cancer. Out-licensed globally to Feng Biosciences Inc. for development and commercialization. Phase 1b data published in Journal of Clinical Oncology.
  • Acumapimod (BCT-197) A novel oral p38 MAP kinase inhibitor in development for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Part of Mereo's clinical-stage pipeline.
  • Leflutrozole A non-steroidal aromatase inhibitor being developed for hypogonadotropic hypogonadism (HH) in reproductive medicine. Out-licensed globally to ReproNovo SA under an exclusive global license agreement.
  • Vantictumab An antibody being developed for osteopetrosis, partnered with āshibio which plans a Phase 2 trial in the second half of 2026.

Quantifiable outcome

  • Phase 3 ORBIT and COSMIC studies showed statistically significant improvements in bone mineral density but did not meet primary endpoint of reducing annualized clinical fracture rates
  • +3 more outcomes

Companies that use Mereo Biopharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Mereo Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Mereo Biopharma partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • Cancer Focus FundminorStrategic or Co-development Partner · 30 April 2021Partnership for Phase 1b/2 study of etigilimab in clear cell ovarian cancer at MD Anderson Cancer Center. Financed by Cancer Focus Fund in exchange for $1.5 million of Mereo shares and milestone payments.
  • AstraZenecacoreTechnology or Integration · 30 October 2017Exclusive license and option to acquire AZD9668 (now alvelestat), an oral inhibitor of neutrophil elastase for alpha-1 antitrypsin deficiency. AstraZeneca previously conducted clinical trials with this compound.
  • Ultragenyx Pharmaceutical Inc.coreStrategic or Co-development PartnerCollaboration and license agreement for global development of setrusumab (UX143) for osteogenesis imperfecta. Partnership includes potential milestone payments of up to $245 million and royalties to Mereo on commercial sales in Ultragenyx territories. Mereo has retained EU and UK commercial rights.
  • āshibiominorStrategic or Co-development PartnerPartner for vantictumab in osteopetrosis. āshibio plans a Phase 2 trial of vantictumab in osteopetrosis for the second half of 2026.
  • Feng Biosciences Inc.minorStrategic or Co-development PartnerGlobal licensing agreement for navicixizumab development and commercialization, including milestone payments and royalties.
  • ReproNovo SAminorStrategic or Co-development PartnerExclusive global license agreement for development and commercialization of leflutrozole, a non-steroidal aromatase inhibitor for reproductive medicine.
  • OncXerna Therapeutics Inc. (formerly Oncologie)minorStrategic or Co-development PartnerPartner for navicixizumab development, previously partnered through OncoMed merger. Phase 1b data published in Journal of Clinical Oncology.
  • CelgeneminorStrategic or Co-development PartnerEtigilimab part of OncoMed's prior collaboration with Celgene. Celgene has option to obtain exclusive license to develop and commercialize the product, with potential $35 million opt-in payment.

Scale indicators6 records

Recent moves8 records

Expansion highlights4 records

Mereo Biopharma competitors and assessment

Company assessment

Direct peers

  • Ultragenyx Pharmaceutical: Ultragenyx is Mereo's primary commercial partner for setrusumab and a directly comparable rare disease biopharmaceutical company. Both companies focus on rare genetic diseases with novel therapeutic approaches and operate capital-efficient development models targeting underserved patient populations.
  • Swedish Orphan Biovitrum (SOBI): SOBI is a specialty biopharmaceutical company focused on rare diseases, with operations in Europe and a model similar to Mereo's capital-efficient approach to acquiring and developing orphan therapies for underserved patient populations.
  • Recordati Rare Diseases: Recordati Rare Diseases is a specialty pharmaceutical company focused on rare diseases with operations in Europe. Their model of acquiring and commercializing rare disease treatments makes them directly comparable to Mereo's strategy.

Broad incumbents

  • BioMarin Pharmaceutical: BioMarin is an established rare disease biopharmaceutical company with bone disorder and enzyme replacement therapies. BioMarin's scale, commercialization infrastructure, and similar therapeutic focus areas make it a relevant comparable for Mereo's rare disease strategy.
  • Alexion Pharmaceuticals (AstraZeneca Rare Disease): Alexion is a leading rare disease biopharmaceutical company (now part of AstraZeneca) with a complementary rare disease franchise. Their specialization in rare genetic disorders and established commercialization infrastructure make them a comparable for Mereo's rare disease business model.
  • Amgen: Amgen developed Evenity (romosozumab), an anti-sclerostin antibody that directly competes with Mereo's setrusumab in bone disorders. Amgen's established presence in bone biology and rare disease therapeutics makes them a relevant comparable.
  • Vertex Pharmaceuticals: Vertex Pharmaceuticals is a specialty biopharmaceutical company that has expanded into rare diseases through its CF franchise and emerging rare disease pipeline. Their capital-efficient R&D model and focus on underserved diseases is comparable to Mereo's strategy.
  • Ipsen: Ipsen is a specialty biopharmaceutical company with rare disease and oncology franchises. Their European commercial infrastructure and focus on specialty care therapies make them relevant for Mereo's commercialization strategy in EU/UK markets.

Emerging players

  • Intercept Pharmaceuticals: Intercept is a smaller specialty biopharmaceutical company focused on rare liver diseases. Their similar capital constraints, regulatory challenges, and reliance on a few key assets provide a comparable profile to Mereo's current situation.
  • Orchard Therapeutics: Orchard Therapeutics is a smaller clinical-stage biopharmaceutical company focused on rare diseases through gene therapy. Their similar size, clinical-stage profile, and focus on rare genetic disorders make them comparable to Mereo's structure and challenges.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Mereo Biopharma social profiles

Digital presence

Mereo Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mereo Biopharma leadership team

Management profile

Number of profiles

Profiles11 records

Mereo Biopharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Mereo Biopharma funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mereo Biopharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mereo Biopharma

What does Mereo Biopharma do?

Mereo BioPharma is a clinical-stage specialty biopharmaceutical company developing novel therapeutics for rare diseases with limited or no treatment options. Its lead pipeline assets are setrusumab (anti-sclerostin monoclonal antibody) for osteogenesis imperfecta and alvelestat (oral neutrophil elastase inhibitor) for alpha-1 antitrypsin deficiency-associated lung disease, complemented by oncology programs (etigilimab, navicixizumab) and other out-licensed candidates. The company uses a capital-efficient acquisition model, taking on therapies deprioritized by larger pharmaceutical companies.

Is Mereo Biopharma a public or private company?

Mereo Biopharma is a public company. It is classified as public and is currently operating.

When was Mereo Biopharma founded?

Mereo Biopharma was founded in 2015. It employs 11 to 50 people.

Where is Mereo Biopharma based?

Mereo Biopharma is headquartered in London, United Kingdom, in the Europe region.

How does Mereo Biopharma make money?

Three revenue lines are on record. Partnership and Milestone Payments are the primary driver. The others are future Product Sales and out-licensed Programs.

Who are Mereo Biopharma's main competitors?

Direct peers on record are Ultragenyx Pharmaceutical, Swedish Orphan Biovitrum (SOBI) and Recordati Rare Diseases. Broad incumbents are BioMarin Pharmaceutical, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Amgen, Vertex Pharmaceuticals and Ipsen. Emerging players are Intercept Pharmaceuticals and Orchard Therapeutics.

Does Mereo Biopharma have an API?

No public API is recorded for Mereo Biopharma.

What industry is Mereo Biopharma in?

Mereo Biopharma's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerMereo BioPharma Group plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Mereo BioPharma reported Q3 and nine-month results for the period ended September 30, 2026. Nine-month sales rose to $0.8 million from $0.5 million a year earlier, while net loss narrowed to $19.59 million from $34.53 million. Basic and diluted loss per share both improved to $0.1 from $0.2.Quiver QuantitativeMEREO BIOPHARMA ($MREO) Releases Q3 2026 Earnings | MREO Stock NewsMEREO BIOPHARMA reported Q3 2026 earnings of -$0.01 per share, beating estimates, and revenue of $800,000, also beating estimates. Hedge fund activity showed 22 institutions added shares while 32 reduced positions, with notable moves by ECOR1 Capital and Millennium Management.MarketBeatMereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Stock Has Average Target Price of $1.67Analysts rate Mereo BioPharma Group's ADR with a consensus 'Hold' and an average price target of $1.67. Institutional investors hold 62.83% of the stock, with several funds increasing positions. The company reported a loss of $0.01 per share for the quarter, meeting estimates.American Banking and Market NewsComparing Ultragenyx Pharmaceutical (NASDAQ:RARE) & Mereo BioPharma Group (NASDAQ:MREO)Ultragenyx Pharmaceutical and Mereo BioPharma Group are compared on profitability, institutional ownership, and analyst ratings. Mereo has higher probable upside (329.55% vs 138.48%) and lower valuation, but Ultragenyx beats on 9 of 14 factors. Analysts favor Mereo due to higher upside.San Diego Business JournalSentynl Watching Over Rare Disease PatientsSentynl Therapeutics, a rare-disease commercialization firm, agreed with Mereo BioPharma to acquire U.S. rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease. The deal includes up to $40 million in fees and a Phase 3 trial planned for early 2027. Sentynl also commercializes three FDA-approved drugs and supports access in over 40 countries.Markets DailyCytokinetics (NASDAQ:CYTK) versus Mereo BioPharma Group (NASDAQ:MREO) Head-To-Head AnalysisCytokinetics and Mereo BioPharma Group are compared on valuation, earnings, and analyst ratings. Mereo has higher earnings and a higher upside potential, beating Cytokinetics on 8 of 14 factors. Analysts favor Mereo, with a consensus target price of $1.67 versus $103.37 for Cytokinetics.American Banking and Market NewsFinancial Survey: Mereo BioPharma Group (NASDAQ:MREO) vs. Protalix BioTherapeutics (NYSE:PLX)Mereo BioPharma Group and Protalix BioTherapeutics are compared on analyst ratings, institutional ownership, and profitability. Mereo has a higher consensus target price and more institutional ownership, while Protalix shows higher revenue and earnings. Analysts favor Mereo due to its higher potential upside.Ticker ReportAnalyzing TScan Therapeutics (NASDAQ:TCRX) & Mereo BioPharma Group (NASDAQ:MREO)Mereo BioPharma Group and TScan Therapeutics are compared on profitability, valuation, and analyst ratings. Mereo has higher earnings but lower revenue, while TScan shows higher potential upside. Analysts favor TScan, with a consensus price target of $2.67 versus $1.67 for Mereo.Ticker ReportMereo BioPharma Group (NASDAQ:MREO) & Veracyte (NASDAQ:VCYT) Head-To-Head ComparisonVeracyte beats Mereo BioPharma Group on 11 of 15 comparison factors, including higher revenue and earnings. Veracyte's consensus price target of $54.33 implies 27.75% upside, while Mereo's $1.67 target implies 566.67% upside. Veracyte also shows stronger profitability and lower valuation.American Banking and Market NewsMereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Consensus Rating of “Hold” by AnalystsMereo BioPharma Group has received an average "Hold" consensus rating from eight covering analysts, with a 12-month price objective of $3.25. The stock recently reported quarterly earnings of ($0.01) per share, meeting analyst estimates, while several hedge funds increased their positions in the company during recent quarters.